Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMX | P51813 | 4/20 | 0.49 |
| ▸ | JAK1 | P23458 | 12/20 | 0.47 |
| ▸ | JAK3 | P52333 | 8/20 | 0.47 |
| ▸ | JAK2 | O60674 | 7/20 | 0.47 |
| ▸ | TYK2 | P29597 | 7/20 | 0.47 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4789715 | 0.90 | BMX (0.58) | BMX | |
| SCHEMBL4789713 | 0.89 | BMX (0.41) | BMXJAK1JAK3JAK2TYK2 | |
| SCHEMBL4789707 | 0.88 | BRAF (0.47) | JAK1JAK3JAK2TYK2MAPT | |
| SCHEMBL4789786 | 0.88 | EGFR (0.43) | BMXJAK1JAK3JAK2TYK2 | |
| SCHEMBL4788889 | 0.85 | BMX (0.53) | BMXMAPT | |
| SCHEMBL4789714 | 0.80 | BRAF (0.48) | BMXMAPT | |
| SCHEMBL4788641 | 0.80 | LCK (0.49) | BMXJAK3 | |
| SCHEMBL4788852 | 0.80 | BRAF (0.43) | BMX | |
| SCHEMBL4788092 | 0.79 | BRAF (0.53) | JAK3 | |
| SCHEMBL14027871 | 0.79 | JAK1 (0.42) | JAK1JAK3JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008144253-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2008-11-27 | — | — | WO | claimed |
| WO-2008144253-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2008-11-27 | — | — | WO | disclosed |